title: [Olaparib in ovarian cancer with BRCA mutation].
abstract: With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient screening, it is usually diagnosed around the age of 60 years at an advanced stage. The emergence of olaparib, a new targeted therapy, represents a major opportunity.
authors.affiliation: Centre des cancers de la femme et recherche clinique, GH Paris Centre, site Hôtel-Dieu, 1 place du Parvis Notre-Dame, 75181 Paris cedex 04, France. Electronic address: epujade@arcagy.org.
authors.forename: Éric
authors.initials: É
authors.lastname: Pujade-Lauraine
authors.affiliation: Service d'oncologie médicale, Hôpital Européen Georges-Pompidou, 20 rue Leblanc, 75015 Paris, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Combe
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D020868:Gene Silencing; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
chemical_list: D000970:Antineoplastic Agents; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C531550:olaparib
keywords: BRCA; Cancer de l'ovaire; Olaparib; Ovarian cancer; PARP